MORE NEWS
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors
scPharmaceuticals Inc. (SCPH) has secured non-dilutive financings totaling up to $125 million with Perceptive Advisors. The deal includes a $75 million senior secured loan and a $50 million revenue interest financing. Key benefits include:
1. Refinancing of existing debt with improved terms
2. Lower interest rate and extended interest-only period
3. Reduced minimum cash requirement to $5 million
4. Additional funding for FUROSCIX commercialization
The revenue interest financing involves tiered single-digit royalties on FUROSCIX global net sales, capped at 1.6x to 2.0x the purchase price. This partnership aims to support FUROSCIX's potential in reducing unnecessary hospital utilization for heart failure patients while generating cost savings for healthcare payers.
1. Refinancing of existing debt with improved terms
2. Lower interest rate and extended interest-only period
3. Reduced minimum cash requirement to $5 million
4. Additional funding for FUROSCIX commercialization
The revenue interest financing involves tiered single-digit royalties on FUROSCIX global net sales, capped at 1.6x to 2.0x the purchase price. This partnership aims to support FUROSCIX's potential in reducing unnecessary hospital utilization for heart failure patients while generating cost savings for healthcare payers.
免責事項：このコミュニティは、Moomoo Technologies Inc.が教育目的でのみ提供するものです。
さらに詳しい情報
コメント
サインインコメントをする
Spread kindness and love. Life is short. Don’t let greed eat you.
2560フォロワー
107フォロー中
28K訪問者
フォロー